BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 10404304)

  • 21. Prostate stem cell antigen predicts tumour recurrence in superficial transitional cell carcinoma of the urinary bladder.
    Elsamman E; Fukumori T; Kasai T; Nakatsuji H; Nishitani MA; Toida K; Ali N; Kanayama HO
    BJU Int; 2006 Jun; 97(6):1202-7. PubMed ID: 16686711
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of cytokeratin 20 in urinary cytology of patients with bladder carcinoma.
    Klein A; Zemer R; Buchumensky V; Klaper R; Nissenkorn I
    Cancer; 1998 Jan; 82(2):349-54. PubMed ID: 9445193
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of circulating MUC7-positive cells by reverse transcription-polymerase chain reaction in bladder cancer patients.
    Kinjo M; Okegawa T; Horie S; Nutahara K; Higashihara E
    Int J Urol; 2004 Jan; 11(1):38-43. PubMed ID: 14678183
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human uroplakin Ib in ocular surface epithelium.
    Adachi W; Okubo K; Kinoshita S
    Invest Ophthalmol Vis Sci; 2000 Sep; 41(10):2900-5. PubMed ID: 10967043
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Uroplakin II gene is expressed in transitional cell carcinoma but not in bilharzial bladder squamous cell carcinoma: alternative pathways of bladder epithelial differentiation and tumor formation.
    Wu RL; Osman I; Wu XR; Lu ML; Zhang ZF; Liang FX; Hamza R; Scher H; Cordon-Cardo C; Sun TT
    Cancer Res; 1998 Mar; 58(6):1291-7. PubMed ID: 9515818
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Urinary bladder transitional cell carcinogenesis is associated with down-regulation of NF1 tumor suppressor gene in vivo and in vitro.
    Aaltonen V; Boström PJ; Söderström KO; Hirvonen O; Tuukkanen J; Nurmi M; Laato M; Peltonen J
    Am J Pathol; 1999 Mar; 154(3):755-65. PubMed ID: 10079253
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cloning of the human uroplakin 1B cDNA and analysis of its expression in urothelial-tumor cell lines and bladder-carcinoma tissue.
    Finch JL; Miller J; Aspinall JO; Cowled PA
    Int J Cancer; 1999 Feb; 80(4):533-8. PubMed ID: 9935153
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transcriptional control of the human urothelial-specific gene, uroplakin Ia.
    Hall GD; Weeks RJ; Olsburgh J; Southgate J; Knowles MA; Selby PJ; Chester JD
    Biochim Biophys Acta; 2005 Jun; 1729(2):126-34. PubMed ID: 15913809
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Loss expression of uroplakin III is associated with clinicopathologic features of aggressive bladder cancer.
    Matsumoto K; Satoh T; Irie A; Ishii J; Kuwao S; Iwamura M; Baba S
    Urology; 2008 Aug; 72(2):444-9. PubMed ID: 18313120
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of uroplakin expression during urothelial carcinogenesis induced by N-butyl-N-(4-hydroxybutyl)nitrosamine in rats and mice.
    Ogawa K; St John M; Luiza de Oliveira M; Arnold L; Shirai T; Sun TT; Cohen SM
    Toxicol Pathol; 1999; 27(6):645-51. PubMed ID: 10588545
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential immunocytochemical staining patterns of uroplakin observed on neoplastic and nonneoplastic tissue fragments obtained from upper urinary tract brush specimens.
    Xu X; Genega EM; Nasuti JF
    Acta Cytol; 2002; 46(4):684-9. PubMed ID: 12146031
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of human uroplakin II promoter and its use in the construction of CG8840, a urothelium-specific adenovirus variant that eliminates established bladder tumors in combination with docetaxel.
    Zhang J; Ramesh N; Chen Y; Li Y; Dilley J; Working P; Yu DC
    Cancer Res; 2002 Jul; 62(13):3743-50. PubMed ID: 12097284
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Loss of FHIT expression in transitional cell carcinoma of the urinary bladder.
    Baffa R; Gomella LG; Vecchione A; Bassi P; Mimori K; Sedor J; Calviello CM; Gardiman M; Minimo C; Strup SE; McCue PA; Kovatich AJ; Pagano F; Huebner K; Croce CM
    Am J Pathol; 2000 Feb; 156(2):419-24. PubMed ID: 10666370
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epigenetic regulation of vascular endothelial growth factor a dynamic expression in transitional cell carcinoma.
    Ping SY; Shen KH; Yu DS
    Mol Carcinog; 2013 Jul; 52(7):568-79. PubMed ID: 22392726
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Altered mRNA expression of the Rb and p16 tumor suppressor genes and of CDK4 in transitional cell carcinomas of the urinary bladder associated with tumor progression.
    Quentin T; Henke C; Korabiowska M; Schlott T; Zimmerman B; Kunze E
    Anticancer Res; 2004; 24(2B):1011-23. PubMed ID: 15161057
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transitional cell carcinomas and nonurothelial carcinomas of the urinary bladder differ in the promoter methylation status of the caveolin-1, hDAB2IP and p53 genes, but not in the global methylation of Alu elements.
    Kunze E; Von Bonin F; Werner C; Wendt M; Schlott T
    Int J Mol Med; 2006 Jan; 17(1):3-13. PubMed ID: 16328005
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The expression of urokinase-related genes in superficial and invasive transitional cell carcinoma.
    McGarvey TW; Kariko K; Barnathan ES; Thomas J; Malkowicz SB
    Int J Oncol; 1998 Jan; 12(1):175-80. PubMed ID: 9454902
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of alpha-fetoprotein and prostate-specific antigen genes in several tissues and detection of mRNAs in normal circulating blood by reverse transcriptase-polymerase chain reaction.
    Ishikawa T; Kashiwagi H; Iwakami Y; Hirai M; Kawamura T; Aiyoshi Y; Yashiro T; Ami Y; Uchida K; Miwa M
    Jpn J Clin Oncol; 1998 Dec; 28(12):723-8. PubMed ID: 9879288
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of epidermal growth factor receptor mRNA in peripheral blood: a new marker of circulating neoplastic cells in bladder cancer patients.
    Gazzaniga P; Gandini O; Giuliani L; Magnanti M; Gradilone A; Silvestri I; Gianni W; Gallucci M; Frati L; Aglianò AM
    Clin Cancer Res; 2001 Mar; 7(3):577-83. PubMed ID: 11297251
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Restoration of bone morphogenetic protein receptor type II expression leads to a decreased rate of tumor growth in bladder transitional cell carcinoma cell line TSU-Pr1.
    Kim IY; Lee DH; Lee DK; Kim WJ; Kim MM; Morton RA; Lerner SP; Kim SJ
    Cancer Res; 2004 Oct; 64(20):7355-60. PubMed ID: 15492256
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.